The importance of establishing the oncogenicity of tyrosine kinase (TK) driver genes is exemplified by the remarkable clinical success of ABL-targeted multi-kinase inhibitors, including imatinib [5] and dasatinib [6], in BCR-ABL1 + and Ph-like B-ALL. Here, BCR is linked to acute lymphoblastic leukemia.